ClinicalTrials.gov
public full text
Public Domain
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey.#421127
- The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP#1150504
- Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity#911056
- OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity#1259207
- Japanese Phase 1 Multiple Ascending Dose Study#1294131
Record · ID 1260629
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive